Clinical trials: Carcinoma, Non-Small-Cell Lung
Stage II Lung Cancer, Lung Cancer
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.
- Conditions
- Stage II Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer, NSCLC
- Trial name
- PERCC (NCT07412041)
- Testing
- PERCC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Non-small Cell Lung Cancer
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic…
- Trial name
- KEYNOTE B36 (NCT04892472)
- Testing
- NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
- Where
- 24 sites in United States
- Volunteers
- 15 people
- Sponsor
- NovoCure GmbH
Non-Small-Cell Lung Carcinoma
Anticancer Activity of Nicotinamide on Lung Cancer
Nicotinamide is an inhibitor of human sirtuins (HDAC III), and is found to re-activate epigenetically silenced tumor suppressors, RUNX3 (runt-related gene 3) and others, in cancer cells.
- Trial name
- NCT02416739
- Testing
- Nicotinamide
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Il Yeong Park, Ph.D.
Non Small Cell Lung Cancer, Healthy
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.
- Trial name
- PROPHETIC (NCT05736029)
- Testing
- blood, stool and tissue samples collection
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- OncoHost Ltd.
Advanced Non-Small Cell Lung Cancer
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
This study will investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy.
- Trial name
- NCT03516981
- Testing
- Pembrolizumab, Favezelimab, Lenvatinib
- Where
- 81 sites in United States, Australia and 14 more
- Volunteers
- 245 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer
A phase II study to assess the efficacy and safety of Surufatinib Combined With Toripalimab and Chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
- Trial name
- NCT05003037
- Testing
- Surufatinib, Toripalimab, Pemetrexed, Carboplatin/Cisplatin
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Li Zhang, MD
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.
- Trial name
- NCT00883675
- Testing
- Docetaxel-Carboplatin
- Where
- 12 sites in United States, China
- Volunteers
- 133 people
- Sponsor
- Michael Mann
Stage IV Non-small Cell Lung Cancer
Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastatic NSCLC
To investigate whether radiotherapy combined with drug therapy is beneficial to non- oligometastatic stage IV NSCLC
- Trial name
- NCT05176067
- Testing
- Thoracic Three-dimensional Radiotherapy
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guizhou Medical University
NSCLC, Advanced Solid Tumor
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
This is an open-label, dose-escalation and cohort expansion study to evaluate the safety and preliminary efficacy of YSCH-01 in subjects with pulmonary metastasis of advanced solid tumors and advanced non-small cell lung cancer…
- Trial name
- NCT07793500
- Testing
- YSCH-01
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small-Cell Lung Carcinoma, Surgery
N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
The objective of this multicenter retrospective study is to compare overall survival in patients with stage IIIA-N2 NSCLC treated with neoadjuvant treatment and surgery versus definitive chemoradiation.
- Conditions
- Non-small-Cell Lung Carcinoma, Surgery, Stage IIIA-N2, Chemoradiation
- Trial name
- NCT02966769
- Testing
- Overall survival
- Where
- Spain
- Volunteers
- 294 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Non-Small Cell Lung Cancer
Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC.
- Trial name
- NCT00633529
- Testing
- IMO-2055
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.
- Trial name
- NCT06908772
- Testing
- Glumetinib Tablets, Osimertinib Mesylate Tablets
- Volunteers
- 390 people
- Sponsor
- Shanghai JMT-Bio Inc.
Lung Cancer
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
This study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy.
- Trial name
- NCT00538681
- Testing
- enzastaurin, pemetrexed, cisplatin
- Where
- 12 sites in Belgium, Germany and 3 more
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of the Lung, Large Cell Lung Cancer
Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC
This phase I trial studies the side effects and best dose of image-guided adaptive radiation therapy using active breathing control when given together with chemotherapy and simultaneous integrated boost in treating patients with…
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer
- Trial name
- NCT02059967
- Testing
- Paclitaxel, image-guided adaptive radiation therapy, carboplatin
- Sponsor
- Virginia Commonwealth University
Non-small Cell Lung Cancer
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2)…
- Trial name
- NCT04297605
- Testing
- Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
Non-Small Cell Lung Cancer, Measles
Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
The objectives of the study are to assess the efficacy and safety of live, attenuated measles vaccine as consolidation therapy in patients with measles-positive, non-small cell lung cancer with locally-advanced (stage 3B with…
- Trial name
- SMC4692 (NCT00828022)
- Testing
- attenuated measles vaccine
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Soroka University Medical Center
Non Small Cell Lung Cancer
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer
The trial is divided into two parts, one is dose escalation phase, the second one is dose expansion phase. For dose escalation phase, the main purpose is to evaluate safety and tolerability of XZP-5809-TT1 tablets after treatment…
- Trial name
- NCT04622072
- Testing
- XZP-5809-TT1 Tablet
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Non-small Cell Lung Cancer, Squamous Cell Carcinoma
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
This randomized, multicenter,open-label phase II/III study is to evaluate the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in patients with stage IIIb-IV squamous non-small-cell…
- Trial name
- CIK (NCT01631357)
- Testing
- CIK cell, Gemcitabine Injection, Cisplatin injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.